公开(公告)号：US11248007B2

公开(公告)日：2022-02-15

申请号：US16492066

申请日：2018-03-08

申请人： Cornell University ,  Dana-Farber Cancer Institute, Inc.

发明人： Nathanael S. Gray ,  David A. Scott ,  John Hatcher ,  Ari M. Melnick ,  Lorena Fontan Gabas

IPC分类号： C07D513/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14

摘要： Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-κB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US20220024929A9

公开(公告)日：2022-01-27

申请号：US17034822

申请日：2020-09-28

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Nathanael S. Gray ,  Yanke Liang ,  Tinghu Zhang ,  Nicholas Paul Kwiatkowski

IPC分类号： C07D487/04 ,  C07D487/10 ,  A61P35/00 ,  A61K31/454 ,  A61K31/4162 ,  A61K45/06

摘要： The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

公开(公告)号：US11225511B2

公开(公告)日：2022-01-18

申请号：US15869537

申请日：2018-01-12

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Stanley J. Korsmeyer ,  Anthony Letai

IPC分类号： C07K14/47

摘要： The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.

公开(公告)号：US20220011296A1

公开(公告)日：2022-01-13

申请号：US17293890

申请日：2019-11-14

申请人： Dana-Farber Cancer Institute, Inc. ,  Massachusetts Institute of Technology

发明人： Keith Ligon ,  Seth William Malinowski ,  Scott R. Manalis ,  Selim Olcum ,  Robert J. Kimmerling ,  Nicholas L. Calistri ,  David Weinstock ,  Mark Murakami ,  Mark M. Stevens

IPC分类号： G01N33/50

摘要： Aspects of the application relate to methods and systems for evaluating treatment response by measuring treatment-induced changes at the single cell level. The disclosure provides methods for isolating single cells that are primary cancer cells, including primary cancer cells from solid tumors, and detecting in minutes to hours from their removal from the body the response of such cells to anti-cancer agents such as radiation, small molecules, biologies, DNA damaging agents and the like.

公开(公告)号：US20210401953A1

公开(公告)日：2021-12-30

申请号：US17293452

申请日：2019-11-13

申请人： The Broad Institute, Inc. ,  President and Fellows of Harvard College ,  Dana-Farber Cancer Institute, Inc.

发明人： William Sellers ,  Haoxin Li

IPC分类号： A61K38/50 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6888 ,  G01N33/574

摘要： Provided herein, in some embodiments, are methods for detecting a level of asparaginase (ASNS) in a sample obtained from a subject having or at risk for stomach cancer or liver cancer, and methods of treating the subject.

公开(公告)号：US11207393B2

公开(公告)日：2021-12-28

申请号：US15768077

申请日：2016-10-14

申请人： President and Fellows of Harvard College ,  The Brigham and Women's Hospital, Inc. ,  Dana-Farber Cancer Institute, Inc.

发明人： Arlene H. Sharpe ,  Gordon J. Freeman ,  Loise M. Francisco ,  Peter T. Sage ,  Sun J. Lee ,  Scott B. Lovitch ,  Vikram R. Juneja ,  Catherine L. Tan

IPC分类号： C07K14/705 ,  A61K35/17 ,  A61K39/395 ,  A61P37/02 ,  A61K38/17 ,  A61K39/00 ,  C07K14/00 ,  A61P35/00 ,  A61K9/00 ,  A61K39/008 ,  A61K45/06

摘要： The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).

公开(公告)号：US11207320B2

公开(公告)日：2021-12-28

申请号：US15752130

申请日：2016-08-12

申请人： The Broad Institute, Inc. ,  Dana-Farber Cancer Institute, Inc. ,  Bayer Pharma Aktiengesellschaft

发明人： Luc De Waal ,  Matthew Meyerson ,  Heidi Greulich ,  Monica Schenone ,  Alex Burgin ,  Xiaoyun Wu ,  Ulrike Sack

IPC分类号： A61K31/50 ,  G01N33/574 ,  A61P35/00 ,  A61K9/00 ,  A61K31/519

摘要： The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).

公开(公告)号：US20210393651A1

公开(公告)日：2021-12-23

申请号：US17289162

申请日：2019-11-07

申请人： DANA-FARBER CANCER INSTITUTE, INC.

发明人： David Frank ,  Erik Nelson

IPC分类号： A61K31/573 ,  A61K45/06 ,  A61P35/00

摘要： The present invention relates to compositions and methods for treating cancer with targeted mineralocorticoid analogues

公开(公告)号：US20210393597A1

公开(公告)日：2021-12-23

申请号：US17289816

申请日：2019-11-07

申请人： DANA-FARBER CANCER INSTITUTE, INC.

发明人： David Frank ,  Erik Nelson

IPC分类号： A61K31/437 ,  A61K31/475 ,  A61K31/505 ,  A61K31/538 ,  A61K31/675 ,  A61K38/17

摘要： The present invention relates to compositions and methods for treating cancer with harmine.

公开(公告)号：US20210379168A1

公开(公告)日：2021-12-09

申请号：US17217864

申请日：2021-03-30

申请人： The Broad Institute, Inc. ,  Dana-Farber Cancer Institute, Inc. ,  The General Hospital Corporation

发明人： Nir Hacohen ,  Catherine Ju-Ying Wu ,  Edward F. Fritsch ,  Ute E. Burkhardt

IPC分类号： A61K39/00 ,  C12N15/10 ,  A61K35/17 ,  C12Q1/6881 ,  G01N33/569

摘要： The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.